Statin-associated muscle-related adverse effects: a case series of 354 patients (Q36509301)

14 August 2017

Statin-associated muscle-related adverse effects: a case series of 354 patients (English)

1 reference

14 August 2017

Stephanie Cham

1

1 reference

14 August 2017

Marcella A Evans

series ordinal

2

1 reference

14 August 2017

Julie O Denenberg

series ordinal

3

1 reference

14 August 2017

Beatrice A Golomb

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

14 August 2017

1 reference

14 August 2017

30

1 reference

14 August 2017

6

1 reference

14 August 2017

541-553

1 reference

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

SLCO1B1 variants and statin-induced myopathy--a genomewide study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Influence of exercise, walking, cycling, and overall nonexercise physical activity on mortality in Chinese women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Exercise for prevention and treatment of cardiovascular disease, type 2 diabetes, and metabolic syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Genetic risk factors associated with lipid-lowering drug-induced myopathies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Clinical perspectives of statin-induced rhabdomyolysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Underappreciated statin-induced myopathic weakness causes disability

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Life-style modification in peripheral arterial disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Statin-associated myopathy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Treating patients with peripheral arterial disease and claudication

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Mitochondrial threshold effects.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Statin-associated myopathy with normal creatine kinase levels

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Muscular side effects of statins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Current and future treatment of hyperlipidemia: the role of statins

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

A critical appraisal of the quality of quality-of-life measurements

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

A method for estimating the probability of adverse drug reactions

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Mitochondrial defects of brain and muscle

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Postmarketing surveillance of adverse drug reactions: patient self-monitoring

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Patient drug attributions and postmarketing surveillance.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Muscle side effects associated with simvastatin therapy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation?

28 June 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Statin safety: an assessment using an administrative claims database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Low and lowered cholesterol and total mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Exercise capacity and mortality among men referred for exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Exercise capacity and body composition as predictors of mortality among men with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Lifetime recreational exercise activity and breast cancer risk among black women and white women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Physical exercise reduces risk of breast cancer in Japanese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Drug-eluting stent restenosis rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Patient reporting of adverse drug reactions: useful information for pain management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Exercise treatment for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.541

Learning from pain scales: patient perspective.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Joggers live longer. The Osterbro study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4729295

Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin

21 September 2018

1 reference

12 December 2020

Exercise for female osteoporosis. A systematic review of randomised clinical trials

1 reference

12 December 2020

New approaches to postmarketing surveillance

1 reference

12 December 2020

Report every adverse drug reaction! We're all in this together.

1 reference

12 December 2020

Reproducibility of pain measurement and pain perception

1 reference

12 December 2020

Postmarketing surveillance: accuracy of patient drug attribution judgments

1 reference

12 December 2020

Simvastatin and side effects

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Observations from a statin myopathy clinic

1 reference

12 December 2020

Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group

1 reference

12 December 2020

Effects of exercise on neurobehavioral function in community-dwelling older people more than 75 years of age

1 reference

12 December 2020

Identifiers

DOI

10.1592/PHCO.30.6.541

1 reference

14 August 2017

1 reference

14 August 2017

1 reference